The FDA released draft guidelines to help drug firms widen their criteria for determining whether an experimental drug could lead to abuse. Biochemistry and chemistry advances have increased the chance that drugs might have unrecognized potential for abuse, the agency said. The final guidelines will be released after two months of consultation with the public and the drug industry.

Related Summaries